Supernus Pharmaceuticals: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 earnings, missing estimated earnings by 323.08% with an EPS of $-0.29 versus an estimate of $0.13. Revenue was down $23.47 million from the same period last year. Last quarter, the company beat EPS estimates but saw a 7.23% drop in share price the next day.
November 08, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals' Q3 earnings missed estimates significantly, which could negatively impact the stock price in the short term.
Supernus Pharmaceuticals reported a significant miss on its Q3 earnings, which is likely to negatively impact investor sentiment and could lead to a decrease in the stock price. This is further supported by the company's history, as it experienced a 7.23% drop in share price the day after beating EPS estimates last quarter.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100